8 Things To Get Rid Of Your Warts At Home
Warts are a prime example of a skin condition that's stubborn, bothersome and a possible source of embarrassment for some. We're told by board-certified dermatologist and skin care founder Dr. Blair Murphy-Rose that these potentially painful bumps and clusters are 'extremely common' and spread when the human papillomavirus (HPV) enters the skin through microscopic breaks or cuts.
'Common warts can occur on many areas of the body, especially the hands and fingers. Plantar warts typically develop on the soles of the feet and palms and can become painful due to pressure,' she says, adding that flat warts, which are often smoother in appearance, are often found in clusters on the face, legs, or backs of the hands.
Given their high contraction rate and potential for reoccurrence (yes, they are contagious), you may be in search of some at-home solutions that can rid your complexion of these bumpy burdens once and for all — and Murphy-Rose says that these treatments certainly do exist.
Both Murphy-Rose and another expert we spoke to suggest consulting your dermatologist before doing any of the at-home treatments that we've rounded up here, based on their product recommendations and guidance.
A cryotherapy kit
Board-certified dermatologist Dr. Noah Gratch at MDCS Dermatology said that cryotherapy, which involves freezing the wart with liquid nitrogen, is a common in-office wart removal treatment. He suggested this Dr. Scholl's Freeze Away kit, which essentially replicates the process at home and claims to start working in just one treatment. Inside this kit is a pressurized canister with 12 freezing applications, 12 precision-tip applicators, and easy-to-follow instructions. Compatible for both common and plantar warts, many reviewers claim that this treatment is effective and minimally painful. "If you find that these treatments are not working, make sure to visit your dermatologist, although most are harmless, it is always good to make sure," Gratch said. Get it from Amazon for $21.07.
A 40% salicylic acid wart-remover stick
Board-certified dermatologist and skin care founder Dr. Blair Murphy-Rose said that salicylic acid-based treatments for warts exist over the counter, and we found this convenient, solid stick formula that contains a 40% concentration. Effective for both common and plantar warts, the Wart Stick has a non-greasy and waxy consistency and can be a good option for larger warts that medicated bandages can't cover or that might be too big for freezing treatments. This pain-free and odorless treatment contains up to 35 applications and claims to adhere to the surface of warts to penetrate to the root for a more effective removal. Get it from Amazon for $11.99.
A freezing kit with a variety of precision tips
Another freezing treatment recommended by Gratch is this advanced wart remover by Skin Clinic, which comes with 12 application tips that are two different sizes, so you can apply the cryogen solution with greater precision and avoid damaging the surrounding skin. The brand claims that this is a medical-grade formula that gets as cold as —67 degrees for effective results. Get it from Amazon for $16.49.
A classic roll of Duck Tape for occlusion removal
According to Murphy-Rose, occlusion therapy involves covering the wart with duct tape to restrict oxygen and suffocate the wart. It might even be useful to cover the wart with duct tape post-treatment application.Duck Tape is a classic and trusted duct tape option that promises strong adhesion, a waterproof backing and conforms to uneven surfaces. If you don't already have a roll at home, you can grab one here in a variety of yard lengths. Get it from Amazon for $7.16+.
Medicated and waterproof bandages
"If you're waiting to see a dermatologist, it's best to keep the area covered with a bandage or medical tape to help reduce the risk of spreading the virus to other areas or to others," said Murphy-Rose.Based on that guidance, we selected these Compound W bandages, which come in a discreet sheer material, come pre-medicated with a salicylic acid-based solution so you can treat your warts while you keep them covered. These strips promise to be waterproof and offer some cushion between the wart surface and high-friction areas like the inside of shoes for more comfort. According to the brand, apply the medicated strip to warts every 48 hours until it's gone. Get it from Amazon for $8.15 (also available in two other styles and a multi-pack).
Medicated cushioning pads for plantar warts
"[Warts] can grow deeper and more painful over time, especially on weight-bearing areas like the feet," said Murphy-Rose.Dr. Scholl's treatment patches are specifically formulated and designed for plantar warts, which are common and appear on the soles of the feet, according to Gratch. We chose to include these medicated and adhesive pads because they contain a 40% concentration of salicylic acid and offer a surrounding cushion to make it more comfortable to stand on your feet.Get them from Amazon for $10.15.
Several pairs of fresh socks
Murphy-Rose explained that warts contain virus particles that can easily be shed onto socks and shoes. "Wearing clean socks daily and avoiding shared footwear like sandals can also help reduce the risk of spreading," she said. In case you need to replenish your existing stock, this highly rated multi-pack from Amazon contains eight pairs of long-stapled cotton socks that are breathable, feature a no-show and non-slip design and promise to be breathable. Shop them in two sizes and four neutral colors. Get them from Amazon for $16.89.
A popular pair of cushioned shower slides
"Warts are more easily spread over moist skin, which helps warts to spread onto feet in areas like public showers or around swimming pools," said Murphy-Rose. These popular waterproof cloud slides, which we selected, can be a great option if you frequent gyms, swimming pools or shared shower spaces so you can avoid contracting warts. They have a lightweight, delightfully bouncy and cushioned sole with an anti-skid outer sole to keep you from slipping. You can get these in gender-neutral sizes and 16 colors. Get them from Amazon for $23.99.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Boston Globe
9 hours ago
- Boston Globe
ICE officers stuck in Djibouti shipping container with deported migrants
Three officers and eight detainees arrived at the only US military base in Africa unprepared for what awaited them. Defense officials warned them of 'imminent danger of rocket attacks from terrorist groups in Yemen,' but the ICE officers did not pack body armor or other gear to protect themselves. Temperatures soar past 100 degrees during the day. At night, she wrote, a 'smog cloud' forms in the windless sky, filled with rancid smoke from nearby burning pits where residents incinerate trash and human waste. Advertisement The Trump administration has urged the Supreme Court to stay Murphy's April order requiring screenings under the Convention Against Torture, which Congress ratified in 1994 to bar the US government from sending people to countries where they might face torture. In a filing in that case Thursday, officials told the Supreme Court that Murphy's order violates their authority to deport immigrants to third countries if their homelands refuse to take them back, particularly if they are serious offenders who might otherwise be released in the United States. Advertisement Officials said the conditions in Djibouti highlight the dangers of Murphy's order. 'A small number of ICE personnel are currently guarding dangerous criminals around-the-clock in a converted conference room, under threat of rocket attacks and other security and health hazards — disrupting the base's operations, consuming critical resources intended for service members, and harming national security,' Solicitor General D. John Sauer said in the filing. In her declaration, Harper said officers and detainees began to suffer symptoms of a bacterial upper respiratory infection soon after deplaning, including 'coughing, difficulty breathing, fever, and achy joints.' Medication wasn't immediately available. She wrote that the flight nurse has since obtained treatments such as inhalers, Tylenol, eye drops, and nasal spray, but they cannot get tested for the illness to properly treat it. 'It is unknown how long the medical supply will last,' Harper wrote. The officers spend their days guarding eight immigrants convicted of crimes that include murder, attempted murder, sex offenses, and armed robbery, court records show. Harper said Defense Department employees 'have expressed frustration' about staying in close proximity to violent offenders. Harper said ICE has had to deploy more officers available to work in 'deleterious' conditions to give the initial crew a break. Currently 11 officers are assigned to guard the immigrants and two others 'support the medical staff,' she said. They work 12-hour shifts guarding immigrants, taking them to get medication and to use the restroom and the shower in a nearby trailer, one at a time. Officers pat down the detainees, searching them for contraband. Advertisement At night and on breaks, officers sleep on bunk beds in a trailer, with one storage locker apiece. Some wear N95 masks even while they sleep because the air is so polluted it irritates their throats and makes it difficult to breathe. The area is dimly lit, which Harper wrote poses a security risk to the officers. Department of Homeland Security officials seized on the court filings to criticize the judge. 'This Massachusetts District judge is putting the lives of our ICE law enforcement in danger by stranding them in [Djibouti] without proper resources, lack of medical care, and terrorists who hate Americans running rampant,' said DHS spokesperson Tricia McLaughlin on X. 'Our @ICEgov officers were only supposed to transport for removal 8 *convicted criminals* with *final deportation orders* who were so monstrous and barbaric that no other country would take them. This is reprehensible and, quite frankly, pathological.' But a lawyer for the detainees said they are also worried about their health, whether they are shackled and, the circumstances that DHS has created for them. 'We're increasingly concerned about the conditions of the detainees,' said Trina Realmuto, an attorney for the deportees. Murphy had said DHS abruptly launched the deportation flight even though it plainly violated his April 18 preliminary injunction barring them from removing people without due process. Federal law prohibits sending anyone — even criminals — to countries where they might be persecuted or tortured. Advertisement Although McLaughlin said officials couldn't deport them to their home countries, Mexico President Claudia Sheinbaum said at a news conference last month that the US government did not inform her of the Mexican national sent to Djibouti, Jesus Munoz Gutierrez, who was convicted of second-degree murder in Florida 20 years ago, court records show.
CNET
17 hours ago
- CNET
Breathe Easy This Allergy Season With 50% Off a Morento Air Purifier
Springtime is rough for a lot of us with all manner of plant life shooting pollen into the air with reckless abandon. But a good air purifier can help keep allergies at bay, at least within the safety of your own home, and right now you can get your hands on the Morento air purifier while it's 50% off at Amazon. That means it's down to just $80, and it's a great way to clear that air up. Make sure you act fast if you want it though, as there's no telling how long this deal will last. The Morento air purifier -- full name Morento HY4866-WF -- can handle rooms up to 1,076 square feet, which is going to be enough for most bedrooms or living rooms. Along with that, it has an air quality display to help you see how well it's doing, and it even comes with a couple of extra filters. That's just good news for general usability, because we all forget to order new ones the first time around. The result of all of this is that you can get rid of pollutants and allergens in the air, and that can help immensely when you're in the middle of allergy season, or if you've got pets you're suffering with a bit. Hey, did you know? CNET Deals texts are free, easy and save you money. In addition to being generally good at clearing the air, it's also smart, meaning you can control it with Alexa, Google Assistant or the accompanying app so that you can turn it on or off without having to get up or set it to run on a schedule that suits you. Given the power and functionality of this device, not to mention the discount, there's no denying that this is one of the best air purifier deals going on right now. Just make sure you act fast to avoid missing out on it. Why this deal matters A solid air purifier can actually improve some peoples' quality of life a fair bit. The ability to take out things like smoke is good, but the real winner here for many of us is the ability to filter out allergens like pollen and dust. Hayfever season is in full swing at the moment, so being able to save 50% on breathing properly is a great deal.
Yahoo
17 hours ago
- Yahoo
Nkarta Appoints Shawn Rose Chief Medical Officer & Head of R&D as Company Resets Senior Leadership Role for Autoimmune Focus
SOUTH SAN FRANCISCO, Calif., June 06, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat autoimmune disease, today announced the appointment of Shawn Rose, M.D. Ph.D., as its next Chief Medical Officer (CMO) and Head of Research and Development (R&D) starting on June 23, 2025. He replaces David R. Shook, M.D., who will be stepping down from the role to pursue other opportunities in the oncology space. Dr. Rose has dedicated his career to immunology translational medicine and advancing new treatment options for autoimmune patients. In various leadership roles, he has brought forward more than a dozen programs from discovery into clinical development, and he has developed multiple pioneering approved medicines such as Sotyktu, Stelara, and Tremfya. 'Dr. Rose joins the Nkarta team at a critical threshold as we discover the power of our NK cell platform to treat autoimmune diseases,' said Paul J. Hastings, CEO of Nkarta. 'He is an enterprise leader with a deep clinical background in rheumatology and immunology that's ideally suited to maximize the potential of our allogeneic NK cell platform. Shawn's proven track record as an expert clinician gives me full confidence that he will hit the ground running on day one and meaningfully advance our work in the clinic.' Dr. Rose most recently served as Chief Development Officer, Immunology, at Vividion Therapeutics, working to expand their portfolio by advancing previously undruggable targets in immunology. He also served as interim CMO and Head of Clinical Development at Magenta Therapeutics, working on cell-based therapeutic approaches for patients with cancer, genetic disorders and immune-mediated inflammatory diseases. Dr. Rose also held multiple clinical and development leadership roles at Annexon Biosciences, Janssen Pharmaceuticals, and Bristol-Myers Squibb. He did his postdoctoral research training and clinical training in Internal Medicine and Rheumatology at the Northwestern University Feinberg School of Medicine. 'I am thrilled to join Nkarta to advance innovative cell therapies for patients,' said Dr. Rose. 'I strongly believe that Nkarta's allogeneic NK cell platform has the potential to be a transformational approach for patients with immune-mediated inflammatory disease. I look forward to working closely with Paul and the broader Nkarta team on developing more treatment options for patients.' During the transition, Dr. Rose will work with Dr. Shook, who will remain on as a consultant through July 11. 'Dave was an early pioneer of NK cell therapy while working under Nkarta's scientific founder, Dario Campana, at St. Jude Children's Research Hospital, and he has tirelessly pursued options that were more convenient for patients with safety utmost in mind,' Hastings said. 'Dave has devoted much of his career to make important contributions to the advancement of natural killer cell therapy, leading our early clinical work in cancer and overseeing key aspects of our strategic shift into a new disease area with agility and flexibility. But Dave is a dedicated oncologist, and he has decided to return to the field he loves. He is a fearless advocate for patients and their well-being and a very good friend who will be missed.' About NKX019NKX019 is an allogeneic, cryopreserved, off-the-shelf immunotherapy candidate that uses natural killer (NK) cells derived from the peripheral blood of healthy adult donors. It is engineered with a humanized CD19-directed chimeric antigen receptor (CAR) for enhanced cell targeting and a proprietary, membrane-bound form of interleukin-15 (IL-15) for greater persistence and activity without exogenous cytokine support. CD19 is a biomarker for normal B cells as well as those implicated in autoimmune disease and B cell-derived malignancies. Nkarta is evaluating NKX019 in multiple autoimmune conditions. About NkartaNkarta is a clinical-stage biotechnology company advancing the development of allogeneic, off-the-shelf natural killer (NK) cell therapies for autoimmune diseases. By combining its cell expansion and cryopreservation platform with proprietary cell engineering technologies, Nkarta is building a pipeline of future cell therapies engineered for deep therapeutic activity and intended for broad access in the outpatient treatment setting. For more information, please visit the company's website at Cautionary Note on Forward-Looking Statements Statements contained in this press release regarding matters that are not historical facts are 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as "anticipates," "believes," "expects," "intends," 'plans,' 'potential,' "projects,' 'would' and "future" or similar expressions are intended to identify forward-looking statements. Examples of these forward-looking statements include, but are not limited to, statements concerning Nkarta's expectations regarding any or all of the following: Nkarta's position, plans, strategies, and timelines for the continued and future clinical development and commercial potential of NKX019 (including the future availability and disclosure of clinical data and other updates from Nkarta's clinical trials). Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties include, among others: Nkarta's limited operating history and historical losses; Nkarta's lack of any products approved for sale and its ability to achieve profitability; the risk that the results of preclinical studies and early-stage clinical trials may not be predictive of future results; Nkarta's ability to raise additional funding to complete the development and any commercialization of its product candidates; Nkarta's dependence on the clinical success of NKX019; that Nkarta may be delayed in initiating, enrolling patients in or completing its clinical trials; competition from third parties that are developing products for similar uses; Nkarta's ability to obtain, maintain and protect its intellectual property; Nkarta's dependence on third parties in connection with manufacturing, clinical trials and pre-clinical studies; the complexity of the manufacturing process for CAR NK cell therapies; and the success of Nkarta's recent (and any future) cost containment measures. These and other risks and uncertainties are described more fully in Nkarta's filings with the Securities and Exchange Commission ('SEC'), including the 'Risk Factors' section of Nkarta's Annual Report on Form 10-Q for the quarter ended March 31, 2025, filed with the SEC on May 14, 2025, and Nkarta's other documents subsequently filed with or furnished to the SEC. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except to the extent required by law, Nkarta undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made. Nkarta Media/Investor Contact:Nadir MahmoodNkarta, in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
